Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 2Platinum-resistant Ovarian Cancer 1Ovarian Cancer Recurrent 1

Interventions

Paclitaxel 77pembrolizumab 65Carboplatin 57Bevacizumab 57Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 35olaparib 31Gemcitabine 27liposomal doxorubicin 25Biopsy 22Taxes 19Cyclophosphamide 18Topotecan 17Nivolumab 17Doxorubicin 16Immunoglobulin G 15niraparib 14Letrozole 14Disulfides 14lenvatinib 13fludarabine 13Surveys and Questionnaires 12Drug Therapy 12Radiotherapy 11Platinum 11atezolizumab 10abemaciclib 10durvalumab 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
1-dodecylpyridoxal × Gynecologic × 90 days × Clear all
NCT07564141 2026-06-03

RAINFOLâ„¢-07

Genmab

Phase 3 Not yet recruiting
688 enrolled
Gynecologic

Ovarian Neoplasms

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05551507 2026-05-04

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡